Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The importance of a dedicated patch test clinic.
Ormond P, Hazelwood E, Bourke B, Lyons JF, Bourke JF. Ormond P, et al. Among authors: lyons jf. Br J Dermatol. 2002 Feb;146(2):304-7. doi: 10.1046/j.0007-0963.2001.04526.x. Br J Dermatol. 2002. PMID: 11903244
Skin-coloured lumps in childhood.
Langan S, Fitzgibbon J, Lyons JF, Bourke JF. Langan S, et al. Among authors: lyons jf. Clin Exp Dermatol. 2006 Jan;31(1):157-8. doi: 10.1111/j.1365-2230.2005.01873.x. Clin Exp Dermatol. 2006. PMID: 16309529 No abstract available.
Treatment of granulomatous cheilitis with infliximab.
Barry O, Barry J, Langan S, Murphy M, Fitzgibbon J, Lyons JF. Barry O, et al. Among authors: lyons jf. Arch Dermatol. 2005 Sep;141(9):1080-2. doi: 10.1001/archderm.141.9.1080. Arch Dermatol. 2005. PMID: 16172303 No abstract available.
Localized linear IgA disease and platelet abnormalities.
Condon C, Cotter P, Lyons JF. Condon C, et al. Among authors: lyons jf. Br J Dermatol. 1994 Jul;131(1):139-41. doi: 10.1111/j.1365-2133.1994.tb08476.x. Br J Dermatol. 1994. PMID: 8043411 No abstract available.
ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK.
Munck JM, Berdini V, Bevan L, Brothwood JL, Castro J, Courtin A, East C, Ferraldeschi R, Heightman TD, Hindley CJ, Kucia-Tran J, Lyons JF, Martins V, Muench S, Murray CW, Norton D, O'Reilly M, Reader M, Rees DC, Rich SJ, Richardson CJ, Shah AD, Stanczuk L, Thompson NT, Wilsher NE, Woolford AJ, Wallis NG. Munck JM, et al. Among authors: lyons jf. Mol Cancer Ther. 2021 Oct;20(10):1757-1768. doi: 10.1158/1535-7163.MCT-20-0909. Epub 2021 Jul 30. Mol Cancer Ther. 2021. PMID: 34330842
Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2.
Heightman TD, Berdini V, Braithwaite H, Buck IM, Cassidy M, Castro J, Courtin A, Day JEH, East C, Fazal L, Graham B, Griffiths-Jones CM, Lyons JF, Martins V, Muench S, Munck JM, Norton D, O'Reilly M, Palmer N, Pathuri P, Reader M, Rees DC, Rich SJ, Richardson C, Saini H, Thompson NT, Wallis NG, Walton H, Wilsher NE, Woolford AJ, Cooke M, Cousin D, Onions S, Shannon J, Watts J, Murray CW. Heightman TD, et al. Among authors: lyons jf. J Med Chem. 2018 Jun 14;61(11):4978-4992. doi: 10.1021/acs.jmedchem.8b00421. Epub 2018 May 31. J Med Chem. 2018. PMID: 29775310
37 results